Table 1.
Demographic and Clinical Characteristics of the Patients at Baseline and Follow-up Data.*
| Characteristic | Treatment (N = 38) | Control (N = 35) |
|---|---|---|
| Median age (IQR) — yr | 64 (54–69) | 60 (49–67) |
| Sex — no. (%) | ||
| Female | 6 (16) | 9 (26) |
| Male | 32 (84) | 26 (74) |
| Race — no. (%)† | ||
| White | 35 (92.1) | 29 (82.9) |
| Black | 2 (5.3) | 3 (8.6) |
| Asian | 1 (2.6) | 2 (5.7) |
| Unknown or not reported | 0 | 1 (29) |
| Median body-mass index (IQR)‡ | 29.6 (25.4–33.6) | 30.7 (26.4–34.6) |
| Primary stone — no. (%) | ||
| Location | ||
| Kidney | 20 (53) | 18 (51) |
| Ureter | 18 (47) | 17 (49) |
| Left side | 20 (53) | 21 (60) |
| Right side | 18 (47) | 14 (40) |
| Removal method | ||
| Ureteroscopy | 33 (87) | 31 (89) |
| Percutaneous nephrolithotomy | 5 (13) | 4 (11) |
| Secondary stone — no. (%) | ||
| Location | ||
| Contralateral | 34 (90) | 32 (91) |
| Ipsilateral | 4 (10) | 3 (9) |
| Median size (IQR) — mm | 3 (3–4) | 4 (2–4) |
| Median no. (IQR) | 1 (1–2) | 1 (1–3) |
| Stone composition — no. (%) | ||
| Calcium oxalate | 33 (87) | 30 (86) |
| Calcium phosphate | 1 (11) | 3 (9) |
| Uric acid | 4 (3) | 0 |
| Other or unknown | 0 | 2 (6) |
| Median follow-up (IQR) — yr | 4.1 (2.9–5.0) | 4.2 (3.5–5.0) |
| Receipt of prescribed medication for stone prevention — no. (%) | 10 (26) | 8 (23) |
*
IQR denotes interquartile range.
†
Race was determined by a review of medical records or was reported by the patient.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.